ACER Acer Therapeutics Inc.

23.61
-0.26  -1%
Previous Close 23.87
Open 24.04
Price To Book 4.47
Market Cap 237351047
Shares 10,052,988
Volume 23,548
Short Ratio
Av. Daily Volume 29,178

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

PDUFA date under priority review June 25, 2019.
EDSIVO
Vascular Ehlers-Danlos Syndrome
Phase 2b trial did not meet primary endpoint - October 28, 2016.
Tovaxin (Tcelna)
Secondary Progressive MS (SPMS)
NDA filing planned for 2019.
ACER-001
Urea cycle disorder (UCD)

SEC Filings

  1. CT ORDER - Confidential treatment order 19610196
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19605483
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19603140
  4. 8-K - Current report 19512343
  5. 8-K - Current report 19500174
  6. 8-K - Current report 181251459
  7. 424B2 - Prospectus [Rule 424(b)(2)] 181199147
  8. EFFECT - Notice of Effectiveness 181199128
  9. CORRESP [Cover] - Correspondence
  10. UPLOAD [Cover] - SEC-generated letter